marketcaparena

argenx SE

ARGX

About argenx

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

argenx.com ↗

Employees
1,863
Business address
ZWIJNAARDE
Fiscal year ends
December 31
Listed
Nasdaq · ARGX

Price

Share price

Daily closing price. The header shows the latest close, the market cap at that close and the change over the selected range. Hover or tap the chart to read any day.
$972.25
+$260.63 (+36.62%)past year
Market cap
$60.2B
At close
Sep 28, 2026

Share price vs index

argenx's share price and the index, each as its percentage change since the first day of the selected range. The shading shows the gap: green while argenx is ahead, orange while it is behind. The values at the end are each one's change over the range.

Income statement

Revenue, gross profit and net income

FY25
Full year
Revenue, gross profit and net income on one scale, so their sizes can be compared period by period.

Income statement

FY23
Full year
How revenue becomes net income in the chosen year or quarter. Solid bars are totals; hatched bars are the costs taken off between them.
TotalAddedSubtracted

Operating leverage

FY25
Full year
Revenue growth against operating expense growth, each against the same quarter a year earlier. While revenue grows faster than opex, each extra dollar of sales keeps more profit.

Cash flow

Operating and free cash flow

FY25
Full year
Free cash flow is what is left of operating cash flow after capital expenditure. The gap between each pair of bars is that year's capex.

Cash flow statement

FY25
Full year
The reported movements behind the change in cash in the chosen year or quarter. Solid bars are totals; hatched bars are what was added or taken off between them.
TotalAddedSubtracted

Capital allocation

FY25
Full year
Operating cash flow above zero; what it was spent on below: capital expenditure, dividends and buybacks.

Stock-based compensation

FY25
Full year
Stock-based compensation reported in the cash flow statement each period. The line is that amount as a percentage of the same period's revenue.
Stock-based compensation% of revenue

Balance sheet

Assets, liabilities and equity

Q4 25
Full year
Quarter
The balance sheet at the end of the chosen year or quarter. What the company owns on the left, against what it owes and what belongs to shareholders on the right. Both columns add up to total assets.

War chest

Q4 25
Full year
Quarter
Cash and short-term investments held at each quarter end. The figure at the top of each column is the total.